Expanded Medicare Advantage Audit Scope Affects Major Insurers

The announcement of an expanded Medicare Advantage audit scope by the Centers for Medicare & Medicaid Services (CMS) has led to a 5% decline in UnitedHealth Group's share price, also adversely affecting Humana and CVS Health stocks.

The proposed CMS rule, referred to as CRUSH, stands to substantially reshape the financial landscape for Medicare Advantage providers by extending audit error rates retroactively to entire contracts dating back to the payment year 2018. This proposal anticipates a broad recovery of approximately $9 billion annually across the industry, with significant implications for companies heavily reliant on Medicare-related revenue. Investors are closely monitoring this development, particularly for companies like Humana, whose fortunes are closely tied to federal contracts.

Impact on Major Players

Humana is especially vulnerable, with 83% of its 2025 revenue stemming from federal contracts, compared to 44% for UnitedHealth. Humana experienced a pronounced 13% share price drop following the announcement, highlighting its exposure and reliance on these contracts. In contrast, UnitedHealth's diversification into employer insurance, Medicaid, and Optum services offers a safety net, mitigating potential financial impacts.

For Humana, the financial risks are stark. With a slim operating margin of 2.5%, a 1% revenue reclamation by audits could slash Humana's total revenue by 0.83%. Such financial strain is likely to ripple through smaller Medicare plans like Alignment Healthcare, which operate with even tighter profitability margins.

Legal and Regulatory Developments

The CRUSH proposal is part of an ongoing regulatory tightening by CMS, following a pattern of heightened scrutiny that includes previous court challenges. Notably, a 2023 rule was overturned by a federal judge, with the current appeal in the Fifth Circuit potentially shifting regulatory dynamics upon resolution. This climate underscores the contentious and evolving state of Medicare Advantage auditing policies.

Looking Ahead: Strategic Implications

Analysts project Humana's earnings per share to rebound significantly, from $9.54 currently to $36.91 by 2028. However, the financial outlook largely predated the CMS proposal, with future earnings contingent upon the outcome of audits and potential revenue recoveries. Humana's upcoming 2027 financial guidance will be crucial, offering insight into its ability to stabilize amidst the anticipated audit effects.

UnitedHealth, while initially impacted by the proposal, appears better positioned to withstand the challenges due to its diversified operations. The CMS comment period, ending in January 2027, will be a pivotal timeframe as the industry anticipates potential adjustments to the rule based on stakeholder feedback.

  • CRUSH proposal applies audit error rates to entire contracts starting from 2018.
  • Potential $9 billion annual recovery anticipated by CMS industry-wide.
  • Humana heavily reliant on federal revenue, faces 13% drop post-announcement.
  • UnitedHealth's diversified portfolio provides partial financial insulation.
  • Legal processes, including an appeal in the Fifth Circuit, remain ongoing.

The coming months will be critical for insurance professionals as they analyze the financial and operational impacts of this regulatory shift. Staying informed and adaptable will be essential as the industry navigates these complex changes.